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Colon targeted drug delivery is highly relevant not only to treat colonic local diseases, 
but also for systemic therapies. Mesoporous silica nanoparticles (MSNs) have been 
demonstrated as useful systems for controlled drug release given their biocompatibility 
and the possibility of designing gated systems able to release cargo only upon the 
presence of certain stimuli. We report herein the preparation of three gated MSNs able 
to deliver their cargo triggered by different stimuli (redox ambient (S1), enzymatic 
hydrolysis (S2) and a surfactant or being in contact with cell membrane (S3)), and their 
performance in solution and in vitro with Caco-2 cells. safranin O dye was used as a 
model drug to track cargo fate. Studies of cargo permeability in Caco-2 monolayers 
demonstrated that intracellular safranin O levels were significantly higher in Caco-2 
monolayers when using MSNs compared to those of free dye. Internalization assays 
indicated that S2 nanoparticles were taken up by cells via endocytosis. S2 nanoparticles 
were selected for in vivo tests in rats. For in vivo assays, capsules were filled with S2 
nanoparticles and coated with Eudragit®FS 30 D to target colon. The enteric coated 
capsule containing the MSNs was able to deliver S2 nanoparticles in colon tissue (first 
step) and then nanoparticles were able to deliver safranin O inside de colonic cells after 
the enzymatic stimuli (second step). This result in high levels of safranin O in colonic 
tissue combined with low dye levels in plasma and body tissues. The results suggested 
that this combination of enzyme-responsive gated MSNs and enteric coated capsules 
may improve the absorption of drugs in colon to treat local diseases with a reduction of 
systemic effects. 
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Research to develop colon-targeted drug delivery strategies is highly relevant not only 
to treat colonic local diseases, but also for systemic therapy. In colonic local diseases, 
treatment with a site-specific delivery system improves therapy effectiveness, a required 
dose can be lowered and fewer side effects appear. Local disorders that affect the colon, 
such as inflammatory bowel diseases (IBD), colorectal cancer and infections, are 
common worldwide and cause major health problems. IBD and colorectal cancer are a 
major cause of morbidity and mortality in western countries. IBD is a group of chronic 
relapsing gastrointestinal diseases, including ulcerative colitis and Crohn’s disease, both 
characterized by cycles of relapsing and remitting mucosal inflammation.
1
 There is no 
current cure for IBD, and today’s therapies focus on maintaining remission from 
inflammatory episodes. Therapy can induce and maintain remission for a time, but 70% 
of IBD patients require surgery.
2
 Moreover, conventional oral therapies result in adverse 
effects and toxicity because of the drug’s distribution around the body. Colorectal 
cancer is the third most commonly diagnosed cancer in males and the second in 
females, with 1.4 million cases and 693,900 deaths estimated in 2012.
3
 Current 
treatment is based on specific systemic chemotherapy or chemotherapy administered 
directly into the hepatic artery in an attempt to reach higher levels in tumor tissue. The 
drugs of choice for colorectal cancer are usually 5-fluorouracil, irinotecan, oxaliplatin, 
or their combinations. Besides side effects, these drugs have specific adverse effects, 
such as hand-foot syndrome, skin painful ulcer (5-fluoracil),
4,5
 neuropathy, painful 
hands and feet, esophageal sensitivity to cold and hot substances, difficulties in 
swallowing liquids (oxaliplatin),
6
 and diarrhea (irinotecan).
7
 
As before mentioned, colon targeting would not only improve treatment of colonic 
diseases like colorectal cancer and IBD, among others, but would also constitute a 
potential alternative route for the systemic absorption of conventional and labile drugs, 
peptides and proteins. The colon is characterized by singular physiological factors 
inside the gastrointestinal (GI) tract, e.g., lower peptidase activity,
8
 reduced enzymatic 
activity,
9
 near neutral pH
10
 and long transit time.
11,12
  
Diverse colon targeting strategies must be resistant to prevent drug release in the upper 
gastrointestinal regions, and also responsive to specific triggering mechanisms to ensure 
prompt drug release in the colon.
8
 Conventional strategies to perform colon target drug 
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delivery usually rely on colonic physiological features, such as colonic bacterial 
enzymes, GI transit time,
13
 pressure arising from intestinal contractions,
14
 or pH 
gradient.
8
 The most commonly used pH-dependent coating polymer to facilitate drug 
delivery to the colonic region is methacrylic acid plus methyl methacrylate ester 
copolymer, marketed as Eudragit S, soluble at pH>7.0 (Rohm Pharma, Darmstadt, 
Germany).  
Once the drug is delivered in colon, absorption is highly challenging, especially with 
peptides, proteins and nucleic acids, given poor mucosal membrane permeability.
15
 The 
high molecular weight, hydrophilicity and hydrogen-bonding capability of these 
molecules complicate their absorption across the mucus-covered epithelium.
15
 Different 
formulation strategies for successful mucosal drug delivery exist. Among them, diverse 
examples of nano- and microparticles have been tested. Nanoparticles generally have a 
high surface-to-volume ratio, and their relatively small size enables deep tissue 
infiltration and, thus, potentially good mucus penetration.
15
 Drug release can occur in 
such a way that it allows the mucosal absorption of the drug, or the particle can be taken 
up and transported into and/or across the mucosa prior to drug release.  
Mesoporous silica nanoparticles (MSNs)
16
 have been used as inorganic scaffolds for the 
storage and release of drugs and organic molecules.
17–19
 The unique features of MSNs 
include high stability, biocompatibility, homogeneous porosity, high inertness and 
functionalization ease, which confer them useful properties as potential drug 
containers.
20,21
 MSNs can be prepared in a wide range of sizes with tailored-made pores 
of around 2-10 nm. MSNs can be functionalized to design gated nanoparticles able to 
display “zero release” until a suitable stimulus is applied, which makes this technology 
optimal to develop new effective drug-delivery nanodevices.
18,21
 Chemical triggers, 











 have been used to develop gated materials with controlled-release 
features.  
In this context, and taking into account the substantial interest shown in the design of 
delivery systems that target the colon, this work presents the preparation of three 
different gated MSNs loaded with safranin O (as a model drug) and capped with 
molecules that contain a disulphide bond (S1),
45
 hydrolyzed starch (S2)
43
 and a lipid 
bilayer (S3).
46
 Uncapping of the nanoparticles in the presence of certain stimuli was 
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studied in both aqueous solutions and Caco-2 cells. Moreover, the permeability of 
safranin O when encapsulated in S1, S2 and S3, compared to that of free dye, in Caco-2 
monolayers (a model for drug transport across the intestinal mucosa) was also studied. 
Finally, in vivo experiments, in which S2 was included in an enteric coated capsule with 
Eudragit ® FS 30 D in rats to study cargo biodistribution (e.g., safranin O), were carried 
out.  
 
2. MATERIAL AND METHODS 
2.1. Chemicals. 
Tetraethylortosilicate (TEOS), n-cetyltrimethylammoniumbromide (CTABr), sodium 
hydroxide (NaOH), tris(2-carboxyethyl)phosphine hydrochloride (TCEP), pancreatin 
from porcine pancreas, dodecyltrimethylammonium bromide (DTABr), 2,2’-dipyridyl 
disulphide, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), safranin O, fluorescein 
isotiocianate (FITC), O-(2-mercaptoethyl)-O’-methylhexa(ethylene glicol), 3-
aminopropyltriethoxysilane (APTES), (3-mercaptopropyl)trimethoxysilane and 3-(4,5-
dimetiltiazol-2-ilo)-2,5-difeniltetrazole bromide (MTT) were provided by Aldrich. 
Glucidex 29 (10% glucose, 9% maltose, 81% oligosaccharides and polysaccharides) 
was provided by Roquette. Tetraethylammonium bromide (99%) was provided by 
Merck. Anhydrous ethanol was obtained by VWR international Eurolab. Chloroform 
and acetonitrile were provided by Scharlab. Eutanax®, HBSS (Hank´s Balanced Salt 
Solution), hepes, penicillin G, streptomycin, fetal bovine serum, DMEM Glutamax, 
PBS-EDTA and trypsin-EDTA were supplied by GIBCO. Ultrapure water was obtained 
in a Millipore QPAK system. 
Synthesis of MSNs 
For the synthesis of MSNs, CTABr (1.00 g, 2.74 mmol) was dissolved in 480 mL of 
distilled water, followed by the addition of 3.5 mL of NaOH 2.00 M. This solution was 
heated to 80ºC and TEOS (5 mL, 25.7 mmol) was added dropwise. The mixture was 
stirred for 2 h at this temperature. A white precipitate was obtained, which was isolated 
by centrifugation. Finally, the solid was washed with distilled water and dried at 70ºC 
(MSN as-synthesized). To prepare the final porous material (MSNs), the as-synthesized 
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solid was calcined at 550ºC for 5 h in an oxidant atmosphere to remove the template 
phase. 
Synthesis of S1 
MSNs were loaded with safranin O dye and coated with molecules that contained a 
disulphide bond. Cargo was released in a reducing environment (S1 nanoparticles). 
MSNs (350 mg) were suspended in a solution of safranin O (98.23 mg, 0.28 mmol) in 
acetonitrile (8.7 mL) in a round-bottomed flask. The mixture was stirred for 24 h at 
room temperature, filtered off and dried under vacuum. The safranin O-loaded MSNs 
(340 mg) were re-suspended in acetonitrile (10.2 mL) in the presence of excess dye, and 
(3-mercaptopropyl)trimethoxysilane (632.48 μL, 3.4 mmol) was added. The suspension 
was stirred for 5.5 h at room temperature. Then 2,2'-dipyridyl disulfide (600 mg, 2.7 
mmol) was added to the reaction mixture. After stirring for 12 h at room temperature, 
the resulting solid was filtered off and dried under vacuum. Finally, a mixture of this 
prepared solid (150 mg) and O-(2-Mercaptoethyl)-O’-methyl-hexa(ethylene glycol) (0.3 
mmol) was suspended in acetonitrile (4.3 mL) in the presence of an excess of safranin 
O. The mixture was stirred for 12 h and final support S1 was isolated by centrifugation, 
washed with abundant water and dried at 40ºC for 12 h. 
Synthesis of S2 and S2b 
MSNs were loaded with safranin O and coated with a starch derivative. Cargo delivery 
occurred via starch hydrolysis in the presence of amylase enzyme (S2 nanoparticles). 
First, the starch derivative was synthesized. Hydrolyzed starch Glucidex 29 (1.0 g) was 
maintained for 1 h under vacuum in a round-bottomed flask to remove the adsorbed 
water. Afterward it was suspended in anhydrous ethanol (50 mL) and APTES (1.17 mL, 
5 mmol) was added. The reaction mixture was stirred in an inert atmosphere for 24 h at 
room temperature and then heated at 60°C for 30 min. The solvent was evaporated 
under reduced pressure to give a white solid (Glu-29).
43
 
MSNs (200 mg) were suspended in a safranin O solution (120 mg, 0.34 mmol) in 
distilled water (6 mL) in a round-bottomed flask. The mixture was stirred for 24 h at 
room temperature. Then excess hydrolyzed starch derivative (Glu-29, 200 mg) was 
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added, and the final mixture was stirred for 5.5 h at room temperature. Finally, solid S2 
was isolated by centrifugation, washed with abundant water, and dried at 40ºC for 12 h. 
MSNs, without safranin O but covalently marked with fluorescein and functionalized 
with Glu-29, were also prepared (S2b). FITC (18 mg) and APTES (10 l) were reacted 
in 1 ml of anhydrous ethanol in the dark for 4 h. Next 0.5 mL of the solution was added 
to MSNs (200 mg), previously suspended in acetonitrile (5 mL), in a round-bottomed 
flask. The mixture was stirred for 12 h at room temperature. The solid was isolated by 
centrifugation and washed with ethanol in a Soxhlet apparatus to eliminate excess 
fluorescein. The FITC-labeled MSNs were dried at 40ºC for 12 h. Then excess Glu-29 
(150 mg) was added to the FITC-labeled MSNs (150 mg) suspended in distilled water 
(4 mL) in a round-bottomed flask. The mixture was stirred for 5.5 h at room 
temperature. Solid S2b was isolated by centrifugation, washed with abundant water, and 
dried at 40ºC for 12 h. 
Synthesis of S3 
MSNs were loaded with safranin O and capped with a lipid bilayer. Cargo was released 
in the presence of a surfactant or being in contact with the cell membrane (S3 
nanoparticles). MSNs (100 mg) and safranin O (60 mg, 0.17 mmol) were suspended in 
distilled water (3 mL) and the mixture was stirred for 24 h at room temperature. 
Afterward a suspension of liposomes was prepared. For this purpose, DOPC (8.9 mg, 
0.01 mmol) was dissolved in chloroform (2 mL) in a glass vial. Chloroform was 
evaporated under a nitrogen flow, and the lipid was dried under vacuum for 1 h to 
remove any residual chloroform, and to obtain films. Then PBS 0.25x (4 mL) was 
added and the medium was sonicated to obtain a cloudy lipid suspension. This cloudy 
liquid was added to the suspension of the MSNs by manual pipetting. The mixture was 
allowed to rest at room temperature overnight. Finally, nanoparticles were isolated by 
centrifugation, washed with abundant water and dried at 40ºC for 12 h. 
2.2. Characterization 
The synthesized materials were characterized by diverse techniques. The powder X-ray 
diffraction (PXRD) studies were performed in a Bruker D8 Advanced diffractometer 
using CuKα radiation to determine the geometry of the empty and loaded MSNs, and to 
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confirm that the loading process and functionalization did not damage the mesoporous 
scaffolding. The transmission electron microscopy (TEM) images were obtained with 
JEOL JEM-1010 to confirm the mesoporous structure in the final functionalized solids. 
N2 adsorption-desorption isotherms were carried out in a Micromeritics ASAP 2010 
automated sorption analyzer. Samples were degassed at 120ºC under vacuum overnight. 
The specific surface area was calculated from the adsorption data by the BET model. 
Pore size was determined following the BJH method. Elemental analyses, 
thermogravimetric analyses (TGA) and 
1
H-NMR spectra were used to determine the 
content of the gating moieties and safranin O. The TGA analyses were performed by 
TGA/SDTA 851e Mettler Toledo equipment, using an oxidant atmosphere (air, 80 
mL/min) with a heating program that consisted of a heating ramp of 10ºC per minute 
from 393 to 1273 K, and a isothermal heating step at this temperature for 30 min. The 
1
H-NMR experiments were performed in a Bruker AV400 spectrometer after dissolving 
the corresponding sample in NaOD/D2O in the presence of tetraethylammonium 
bromide as an internal standard. To determine the zeta potential of the bare and 
functionalized nanoparticles (S1-S3), a Zetasizer Nano ZS equipment (Malvern 
Instruments, Malvern, UK) was used. Samples were dispersed in distilled water at a 
concentration of 1 mg/mL. Before each measurement, samples were sonicated for 2 min 
to preclude aggregation. The zeta potential was calculated from the particle mobility 
values by applying the Smoluchowski model. The measurements were performed at 25 
ºC and performed in triplicate. Dynamic light scattering (DLS) studies for the 
determination of particle size were conducted at 25 ºC in a Malvern Zetasizer Nano ZS 
instrument; all the measurements were taken in triplicate on previously sonicated water 
dispersions. 
2.3. Delivery studies. 
Delivery studies from S1, S2 and S3 in solution were performed using appropriate 
stimuli. The delivery experiments of S1 were carried out in solution using TCEP as a 
reducing agent. Specifically, S1 (0.5 mg) was suspended in distilled water (2.7 mL, pH 
7.5) and 30 µL of TCEP solution (10 mM) were added. For S2, the delivery 
experiments in the presence of pancreatin as a stimulus were carried out. S2 (4 mg) was 
suspended in distilled water (7.5 mL, pH 7.5) and 2.5 mL of enzyme solution (0.4 g 
pancreatin / 100 mL) were added. For the S3 material, delivery experiments were 
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carried out in solution using surfactant DTABr as a stimulus. S3 (0.5 mg) was 
suspended in distilled water (2.7 mL, pH 7.5) and DTABr solution (10 mM) was added. 
Suspensions of S1, S2 and S3 were stirred and the amount of dye released from the 
different materials in the presence of the respective stimuli was determined by 
measuring the safranin O emission at 575 nm in the solution according to time. In all 
cases nanoparticles were removed by centrifugation (13000 rpm, 3 min). Identical 
experiments using solids S1, S2 and S3, but in the absence of stimuli, were also carried 
out.  
2.4. In vitro cytotoxicity studies 
The Caco-2 cell line (ATCC) was selected to perform studies of nanoparticles in cells 
according to their ability to form simulative intestinal epithelial cell monolayers, which 
is useful to study crossing process-related transport mechanisms.
15,47,48
 The ability of 
MSNs and coated particles S1, S2 and S3 to interfere with the growth of Caco-2 cells 
was determined in vitro by the MTT method.
49
 The effect of doxorubicin (10 mM) as a 
positive control was also studied by the MTT method. The mitochondria of living cells 
are able to convert MTT (a yellow-colored compound) into formazan (a blue-colored 
compound). Blue metabolite appearance can be spectrophotometrically quantified and 
the absorbance value is proportional to the remaining living cells. 
Caco-2 cells (38 passages) were grown in DMEM high glucose supplemented with 1% 
of non-essential amino acids, 10% fetal bovine serum and 1% penicillin/streptomycin. 
25,000 cells per well were seeded in a total volume of 200 µL of culture medium in 96-
well microtiter plates with flat-bottomed wells. Cultures were incubated at 37ºC in a 5% 
CO2 atmosphere. After 24 h, the medium was replaced with fresh medium and MSNs 
S1, S2 or S3 were added (1 mg/mL). Plates were incubated for 24 h, 48 h, or 72 h. Then 
20 µL of 5 mg/mL of the MTT solution were added to each well. Plates were incubated 
at 37ºC for 3 h to allow formazan formation in wells. The liquid medium of each well 
was removed and the dark blue precipitate was dissolved in DMSO. Negative controls 
(solvent alone and untreated cells) were also performed. Assays were carried out in 
quadruplicate for each treatment. Absorbance was measured at 570 nm with a 
Labsystems Multiskan EX plate reader and the values were corrected with a reference to 
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the measurement at 630 nm. Data were expressed as a percentage of the absorbance of 
untreated cells. 
2.5. In vitro permeability studies and transport mechanism analysis 
In vitro permeability, intracellular uptake and inhibition studies were performed on the 
Caco-2 cell monolayers. 
Cell monolayer cultures 
The Caco-2 cell monolayers were prepared by seeding 25,000 cells on a polycarbonate 
membrane placed on the base of transwell inserts (MILLICEL

-PCF, surface area 4.2 
cm
2
, 0.4 µm pore size).
50,51
 Cultures were grown in Dulbecco’s modified Eagle’s media, 
as described previously,
52,53
 until confluence, and were maintained under standard 
conditions (37C with 90% humidity and 5% CO2) for 19-22 days. The integrity of each 
cell monolayer was tested by measuring its transepithelial electrical resistance (TEER) 
value before and after each transport assay. The normal TEER values for the Caco-2 




 The cell monolayers with TEER 
values below 420 cm
2 
were ruled out. Hank’s balanced salt solution (9.8 g/L) 
supplemented HEPES (5.96 g/L) was used for all the experiments after adjusting pH to 
7.0.
52,53
 The system used, that contained a well with an insert placed therein, is formed 
by three compartments: (i) the apical compartment or donor chamber, which mimics the 
intestinal lumen; (ii) the basal compartment or receiving compartment, which represents 
plasma; (iii) the Caco-2 monolayer, which reproduced the intestinal barrier. 
Permeability studies of free safranin O, S1, S2 and S3 
The transport studies of free safranin O and encapsulated in nanoparticles S1, S2 and S3 
(1 mg/mL) were studied at an equivalent dye concentration. The tested nanoparticles 
were loaded onto the donor side and buffer was added to the receiver chamber of each 
well. Assays were performed from the apical-to-basolateral direction in the Caco-2 cell 
monolayers to simulate physiological conditions. The 6-well plate that contained the 
inserts with the cell monolayers was placed into an orbital environmental shaker, and 
was maintained at a constant temperature (37 C) and agitation rate (50 rpm) throughout 
all the experiments. Assays were carried out at 1, 2, 4, 6, 9 and 24 h. Safranin O was 
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determined in the compartments by the collection of samples from donor and receptor 
compartments and from the Caco-2 monolayers. To determine safranin O content in 
monolayers, cell lysates were obtained. Inserts were washed with saline solution (NaCl 
0.9% in double distilled water) and membranes were first frozen in liquid nitrogen and 
later thawed in a water bath. Membranes were mixed with methanol and centrifuged 
(8000 rpm). Finally, the supernatant was taken and the amount of safranin O was 
determined. 
The safranin O concentration in each compartment and in the monolayer cell lysates 
was determined by an HPLC analysis with a fluorescence detector (ex 520 nm; em 585 
nm) using a mobile phase (v/v) 30:70 acetonitrile:water with 1% of trifuoroacetic acid. 
A Novapack C18 (WATERS) cartridge-type column (5 µm, 4 mm x 200 mm) was 
used. 
Imaging study of the intracellular uptake of nanoparticles (studies with S2 and 
S2b) 
The uptake of nanoparticles S2 and S2b into the Caco-2 monolayers was studied 
qualitatively by a fluorescence analysis. A suspension of nanoparticles S2 or S2b (1 
mg/ml) was added to the donor compartment and was co-incubated in standard buffer 
(17.5 μL per 100 μL of buffer). At scheduled times, donor compartments were emptied 
and monolayers were washed with PBS. The fluorescent images of each well were 
obtained by a high content multiwell plate reader Cytation 3 (BioTek Instruments, Inc.) 
and processed using the GEN 5 v2.05 (BioTek Instruments, Inc.) software. Images were 
captured by Texas red (ex 585 nm, em 647 nm), green fluorescent protein (ex 469 nm, 
em 525 nm) and bright field filters every 30 minutes over a total time of 24 h to 
determine safranin O and fluorescein distribution in the monolayers with suspension S2 
and suspension S2b, respectively. 
Mechanism analysis using inhibiting agents 
In order to evaluate the endocytosis mechanism involved in the uptake of S2 by Caco-2 
cells, assays in both the presence and absence of different endocytosis inhibitors 
(chlorpromazine, nystatin or methyl-β-cyclodextrin (MβCD) + lovastatin) were carried 
out. Chlorpromazine is able to inhibit the endocytic process mediated by the receptor 
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and clathrins. Nystatin inhibits caveolae/lipid raft-mediated endocytosis. The MβCD 
and lovastatin mixture is used as an inhibitor of clathrin and caveolae-mediated 
endocytosis.  
For this purpose, the Caco-2 monolayers were pre-incubated with 500 µL of the 
different inhibitors (chlorpromazine 10 µg/mL, nystatin 50 µg/mL and a mixture of 
MβCD 10 mM and lovastatin 1 µg/mL). After 1 h, nanoparticles S2 (1 mg/mL) were 
added to the apical side of the insert and mixtures were incubated for 2 h. Assays in the 
absence of inhibitors were also performed. Safranin O was determined in the cell 
monolayer following the same procedures used before (vide ante). 
2.6. In vivo tissue distribution studies 
To assess the in vitro results, in vivo experiments with S2 (which showed the best 
performance in solution and in cells) in rats were carried out and safranin O 
biodistribution was studied. The animal study was approved by the Scientific 
Committee of the Faculty of Pharmacy of the Universidad Miguel Hernández, Elche 
(project reference DI-MBS-001-12) and followed the guidelines described in EC 
Directive 86/609, the Council of the Europe Convention ETS 123, and were in 
compliance with Spanish national laws about using animals in research (Spanish Royal 
Decree 223/ 1988, BOE 67, 18-3-98:8509-8511).  
Preparation of enteric-coated capsules 
The enteric capsules filled with S2 were coated with Eudragit®FS 30 D (an anionic 
copolymer of methyl acrylate, methyl methacrylate and methacrylic acid). Eudragit®FS 
30 D dissolves from pH 7.2 allowing capsule disintegration. An aqueous dispersion 
30% (w/w) was used for the coating experiments. The enteric capsules filled with S2 
were coated using a spray system. Disintegration control assays were performed at 
different pHs (1.2, 4, 5 and 7.5) in order to verify the proper behaviour of the coating. 
The capsules retained its structural integrity during 2 hours at pH = 1.2, 4 and 5 but 
disintegrated in less than 10 minutes at pH = 7.5. Capsules coated with Eudragit®FS 30 




Male rats were fasted for 4 h (24 rats). S2 were administered to rats (12 rats) orally at a 
dose of 40 mg of S2 in an enteric capsule covered by Eudragit®FS 30 D. In a control 
group (12 rats), a 0.04 mg dose of free safranin O was administered to each rat as 
solution orally. Animals were sacrificed at 24 h, 48 h and 72 h after administration (4 
animals at each time and per administration type). Blood samples were withdrawn and 
several tissues (liver, kidneys and spleen) were excised. 
Blood volume and tissue weight were measured. Tissue was washed with PBS and 
wiped with a filter paper. Then PBS was added by a 3-fold volume of tissue weight, and 
was homogenized in a glass homogenizer with a teflon pestle and mixed. Blood and the 
homogenate tissue were centrifuged at 3,000 rpm for 10 min. After centrifuge the 
homogenate or blood, the supernatant was diluted with PBS, and was deproteinized 
with acetonitrile. Afterward the safranin O concentration in each sample was 
determined by HPLC analysis with a fluorescence detector (ex 520 nm; em 585 nm) 
using a mobile phase (v/v) 30:70 acetonitrile:water with 1% of trifuoroacetic acid. A 
Novapack C18 (WATERS) cartridge-type column (5 µm, 4 mm x 200 mm) was used.  
 
3. RESULTS AND DISCUSSION 
3.1. Gated materials and delivery studies in solution 
In order to prepare the different gated nanodevices described herein, MSNs were 
selected as an inorganic support because of their homogenous porosity, strong inertness 
and well-known functionalization chemistries. Safranin O dye was loaded into the pores 
of MSNs to act as cargo. Polyethylene glycol (PEG) chains that contain a disulphide 
bond,
45
 hydrolyzed starch (Glu-29)
43
 or a lipid bilayer prepared with DOPC,
46
 were 
selected as switchable gate-like ensembles and used as capping ensembles on the 
external surface of materials to obtain solid S1, solid S2 and solid S3, respectively (see 
Figure 1). We expected to observe “zero cargo release” from these nanoparticles until 
the corresponding stimuli was applied; i.e. a reducing agent (for S1), pancreatin (a 
mixture of digestive enzymes, including amylase, lipase and protease) (for S2) and a 






Figure 1. Preparation of gated mesoporous silica nanoparticles S1, S2 and S3 and the 
uncapping mechanism in the presence of the corresponding stimuli.  
Nanoparticles characterization 
MSNs and solids S1, S2 and S3 were characterized by standard techniques. The PXRD 
of MSNs as-synthesized showed four low-angle reflections typical of a hexagonal array, 
which can be indexed as (100), (110), (200), and (210) Bragg peaks (see Supporting 
Information). A significant displacement of the (100) peak in the PXRD of the MSNs 
was clearly noted and was related to further condensation of the silanol groups in the 
calcination step. The intensity of the (100) reflection in the final solids evidenced that 














































mesoporous 3D scaffolding. Presence of the mesoporous structure in the final solids 
was also confirmed by a TEM analysis (see Supporting Information). 
The N2 adsorption-desorption isotherms of MSNs showed two sharp adsorption steps 
(see Supporting Information). The first step at an intermediate P/P0 value (0.1-0.3) was 
related to the nitrogen condensation inside the mesopores by capillarity. Absence of a 
hysteresis loop in this interval and the narrow BJH pore distribution suggested the 





calculated by the BJH model on the adsorption branch of the isotherm. The application 





From the PXRD and porosimetry, the a0 cell parameter (43.16 Å), pore diameter (2.64 
nm) and wall thickness (1.74 nm) were calculated. A second feature appeared in the 
isotherm at a high relative pressure (P/P0> 0.8), which corresponded to the filling of the 




 (calculated by the 
BJH model), which must be considered a textural-like porosity. In this case, the curves 
showed a characteristic H1 hysteresis loop and a wide pore size distribution.  
The N2 adsorption-desorption isotherms of S1, S2 and S3 were typical of mesoporous 
systems with filled mesopores. The most relevant feature was the lack of a sharp step at 
low-medium relative pressure (0.1 < P/P0 < 0.3). In fact these solids showed flat curves 
compared (on the same scale) to those of the starting MSNs parent material, which 
indicated significant pore blocking and the subsequent absence of appreciable 
mesoporosity. Consequently, a relatively low N2 adsorbed volume and decreases in the 
surface area were observed. A certain textural porosity was preserved in these final 
functionalized nanoparticles. The BET specific surface values, pore volumes, and pore 
sizes calculated from the N2 adsorption-desorption isotherms of the starting MSNs and 








Table 1. BET-specific surface values, pore volumes and pore sizes calculated from the 




















MSN 1067.7 0.89 2.64 
S1 99.0 0.25 - 
S2 120.8 0.39 - 
S3 312.3 0.69 - 
a
Volume (V) and diameter (D) of mesopores. 
Dynamic light scattering measurements resulted in values of hydrodynamic diameters 
of 107.1, 134.1, 229.9 and 195. 3 nm for the starting calcined MSNs and S1, S2 and S3, 
respectively (see Table 2). Moreover, zeta potential values of -36.5, 3.76, 2.73 and -3.14 
mV were obtained for the calcined MSNs, S1, S2 and S3 nanoparticles (see also Table 
2). Besides, PDI values of the different nanoparticles prepared are also shown in Table 
2. As could be seen S2 nanoparticles, coated with the hydrolyzed starch, presented the 
higher hydrodynamic diameter. On the other hand calcined MSNs showed a negative 
zeta potential of -36.5 mV due to the presence of silanolate groups on its outer surface. 
In a clear contrast, the capped materials showed strong reductions in the z potential 
values (positive for S1 and S2 and negative for S3) due to the presence of different 
organic moieties grafted/adsorbed onto the external surface of the nanoparticles.  
 
Table 2. Hydrodynamic diameter measured by DLS and surface zeta potential of MSN, 

















MSN 107.1 ± 39.2 -36.5 ± 0.64 0.354 
S1 134.1 ± 18.5 3.76 ± 0.24 0.444 
S2 229.9 ± 28.2 2.73 ± 0.52 0.451 
S3 195.3 ± 32.6 -3.14 ± 0.13 0.548 
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Finally, the content (see Table 3) of the different gating moieties and safranin O in S1, 
S2 and S3 was determined by combining elemental, thermogravimetric analyses and 
1
H-NMR studies after dissolving silica nanoparticles in a basic medium.  
Table 3. Safranine O content and capping moieties for solids S1, S2 and S3 in g g
-1 
solid.  
 Safranin O Glu-29 DOPC PEG 
S1 0.058 - - 0.273 
S2 0.036 0.079 - - 
S3 0.121 - 0.023 - 
Delivery studies in solution of S1, S2 and S3 
In a first step, and before performing in vitro studies in cells, the response of the 
different prepared gated MSNs in solution in both the presence and absence of 
triggering stimuli was studied. Similar systems to those studied herein have been 
reported in the literature.
21
 In particular, S1 was expected to be opened due to the 
reduction of the disulphide bond by TCEP, S2 was expected to deliver the cargo via the 
hydrolysis of the starch gate in the presence of pancreatin, while S3 was expected to be 
opened by the rupture of the lipid bilayer induced by the presence of surfactant DTABr. 
In all cases, the solids remained capped in solution, whereas clear cargo delivery was 
observed in the presence of the corresponding stimulus (see Figure 2). Further tests, 
including the application of an unsuitable stimulus to the corresponding gated materials, 
resulted in no cargo delivery, which indicates the role of the gated ensembles in 
nanoparticles. For instance, S3 was able to deliver the cargo in the presence of DTABr, 
whereas S3 remained capped in the presence of pancreatin and TCEP. S2 was also 
confirmed to be unable to deliver its cargo in the presence of other enzymes other than 
pancreatin. Regarding the delivery profile, differences were found between the distinct 
capped MSNs. Figure 2 shows that dye delivery was relatively fast for S1 and S3 (80% 
of the total delivered cargo was released in under 20 min), whereas a slower cargo 
release was observed for S2 (80% of the total dye delivered was released after ca. 2-4 
h). Besides Figure 2D also showed the crucial role played by the gating ensemble in the 
stimuli controlled release performances of S1, S2 and S3 nanoparticles. As could be 
seen, a nearly instantaneous safranin O release from uncapped MCM-41 nanoparticles 




Figure 2. Safranin O release profile from A) S1, B) S2 and C) S3 in the absence or 
presence of the corresponding stimuli (TCEP (0.1 mM), pancreatin (4 mg/mL) and 
DTABr (0.1 mM) respectively). D) Safranin O release profile from a loaded uncapped 
MSN and S1, S2 and S3 in the absence of the corresponding stimuli. 
A similar behavior in gate opening terms was expected to occur for solids S1, S2 and S3 
(vide infra) upon analogous stimuli in a physiological context. In fact a number of 
studies have demonstrated that MSNs are easily endocytosed by cells, and S1, S2 and 
S3 are expected to deliver their cargo via the stimuli present in cells.
18
 For instance, S1 
is expected to be opened upon internalization in cells by glutathione (a reducing agent at 
a high concentration in cells), whereas S2 would open through the hydrolysis of the 
starch gate due to the presence of amylases in lysosomes. S3 is also expected to deliver 
the cargo in cells upon the fusion of the cell membrane with the lipid bilayer (vide 
infra).  
3.2. In vitro cytotoxicity studies 
Caco-2 cell cultures were used herein to perform cytotoxicity studies when using the 
different nanoparticles. Caco-2 cell viability in the presence of the starting bare MSNs 
and final capped solids S1, S2 and S3, at a concentration of 1 mg/mL, was evaluated by 
MTT assays. Cell survival was evaluated at 24 h, 48 h and 72 h, and the results are 






























































































depicted in Figure 3. The data in the figure suggest that silica nanoparticles (both coated 
and uncoated) did not affect cell growth compared to the control values at 24 h. The 
cytotoxicity effect of 10 M free doxorubicin was compared to all the materials. The 
drug served as a positive control in order to demonstrate the safety of the silica 
materials. At the longer times of 48 and 72 h, presence of MSNs or S1-S3 nanoparticles 
barely had any influence on cell growth. Remarkably, the cells incubated with S2 
showed the best survival results among all the solids, with survival values close to 
100% at 72 h. These results were better than those obtained when cells were incubated 
with S1 or S3, with survival near to 80%, and were also higher than the cells incubated 
with bare MSNs, with survival close to 90% at 72 h.  
 
Figure 3. Percentage of Caco-2 cells survival after treatment with MSNs, S1, S2, S3 
and with free doxorubicin (as positive control) for 24, 48 or 72 h. Data represent the 
means of the experiments performed in quadruplicate. 
3.3. In vitro permeability results 
Transport studies 

























Caco-2 cell monolayers (a standard model for drug transport across the intestinal 
mucosa) were used herein to test the permeability of safranin O when encapsulated in 
S1, S2 and S3, compared to that of free dye. Specifically, transport studies of free 
safranin O and encapsulated within nanoparticles S1, S2 and S3 (1 mg/mL) were 
studied at an equivalent dye concentration. Safranin O content was measured in both the 
cell monolayer and receptor compartment. Figure 4 shows the percentage of safranin O 
measured in these compartments according to time. 
Figure 4. Percentage of safranin O in monolayer (black) and in the receptor 
compartment (grey) obtained from apical to basal (Pab) assays at different times in the 
Caco-2 cell line. a) free safranin O; b) safranin O encapsulated in solid S1 c) safranin O 
encapsulated in solid S2; d) safranin O encapsulated in solid S3. Data correspond to the 
values of three independent experiments.   









































































Free dye rapidly diffuses through the cell monolayer (see Figure 4a), as expected since 
it is a hydrophilic substance. In this case, the safranin O values in the receptor 
compartment were very high compared to the values in the monolayer at all times. The 
safranin O concentrations in the monolayer and receiving compartment did not vary 
with time after 1 h of free dye administration in the donor compartment, which indicates 
that the equilibrium was quickly reached in the system. Under these conditions the 
amount of safranin O inside cells was very small in all cases (data for the monolayer in 
Figure 4a). However, when safranin O was encapsulated, the distribution of the drug 
into the monolayer and receptor compartment was quite different and changed over time 
(see Figure 4b, 4c and 4d). The main difference between using free and encapsulated 
safranin O in S1, S2 and S3 was that dye delivery from nanoparticles could occur only 
within cells after endocytosis in the presence of the corresponding stimulus. As 
commented above, S1 opened and delivered the cargo in the presence of a reducing 
agent (most likely glutathione inside cells), whereas it was the presence of amylase 
enzyme that induced cargo release in the S2 nanoparticles via the hydrolysis of capping 
starch into glucose. At a certain time, the amount of delivered cargo in cells was 
governed by endocytosis kinetics, which was expected to be similar in S1 and S2, and 
by the uncapping process. For S1, the reduction of disulfide bonds was rather quick 
(Figure 3), whereas delivery from S2 was expected to depend on the amylase 
concentration and enzyme activity, and was slower. For S3, delivery occurred when the 
capping lipid bilayer merged with the cell membrane and nanoparticles internalization 
was achieved. For all the nanoparticles, part of the cargo, after delivery inside cells, was 
capable of crossing the basolateral membrane of Caco-2 cells and reaching the receiving 
compartment, which mimics plasma (data shown as the receptor in Figure 4). 
In terms of safranin O intracellular levels in the Caco-2 monolayer, higher values were 
found when using nanoparticles compared with the values found when dye was not 
encapsulated. The largest cargo levels inside cells after 24 h was observed when using 
coated MSNs S1 and S2. 
One goal in local diseases that affect the colon is to be able to deliver high levels of the 
drug in the affected tissue (e.g., in tumors, inflamed tissues, etc.) to prevent drug 
transport across the intestinal barrier in order to improve the efficacy of therapeutics, 
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reduce systemic toxicity and minimize adverse effects. In this context, our results 
suggested that solids S1, S2 and S3 allowed the amount of cargo inside cells to 
significantly increase by minimizing, at the same time, the quantity of cargo that 
reached the receptor compartment. Among the tested solids, nanoparticles S2 were 
selected to perform additional in vitro and in vivo assays to demonstrate that targeting 
delivery in colon can be achieved. S2 nanoparticles seemed the best option since they 
showed optimal cells survival (cytotoxicity assays, vide ante) and displayed high cargo 
delivery inside cells at 24 h. 
Intracellular uptake and uptake mechanism 
Further assays with S2 and the Caco-2 monolayers, involving fluorescence images from 
Caco-2 incubated with these nanoparticles, showed a rather low fluorescence in cells 
due to safranin O after 1-2 h, whereas the dye concentrations in cells clearly increased 
with incubation time (see Figure 5). These data agree with the results observed in the in 
vitro transport assays (see Figure 4c). Moreover, in order to corroborate that Caco-2 
cells endocytosed nanoparticles, similar fluorescence images were taken when the 
fluorescein-labeled S2b solid (fluorescein was covalently attached to nanoparticles) was 
used (see also Figure 5). This experiment clearly indicated that the amount of 
nanoparticles inside cells increased with time and a clear difference in fluorescence was 






















Figure 5. Fluorescence images obtained from the Caco-2 monolayer incubated with the 
S2b nanoparticles after 1 and 24 h. Fluorescence images obtained from the Caco-2 
monolayers incubated with S2 nanoparticles after 1, 2, 4, 9, 12 and 24 h. 
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It is known that internalization inside cells can be carried out by several mechanisms, 
such as clathrin-mediated endocytosis, caveolae-mediated endocytosis and caveolae-
independent endocytosis.
55-57
 In order to gain insight into the internalization of S2, the 
effect of several inhibitors (e.g. chlorpromazine, nystatin, or the methyl-β-cyclodextrin 
+ lovastatin mixture) in the uptake of the nanoparticles in Caco-2 monolayers was 
studied. In particular, Figure 6 shows the amount of safranin O (delivered from S2) in 
the monolayer compartment in both the absence and presence of inhibitors after 2 h. As 
seen, the safranin O concentration in the monolayer lowered by more than 50% in the 
presence of chlorpromazine and nystatin, whereas this value became even larger (up to 
80%) in the presence of methyl-β-cyclodextrin + lovastatin. These results clearly show 
that nanoparticles enter cells via endocytosis and suggest that several endocytosis 
mechanisms are active at the same time.   
 
Figure 6. Percentage of safranin O in the cell monolayer when S2 was placed in the 
apical compartment in the absence and presence of the inhibitors of the different 
mechanisms of endocytosis (Chlor: chlorpromazine; Nyst: nystatin; MβCD+ Lov: 
methyl-β-cyclodextrin + lovastatin).  
3.4. In vivo tissue distribution studies 
Caco-2 monolayers are a standard model for drug transport across the intestinal mucosa. 
Nevertheless, the use of in vitro models has limitations since physiologically relevant 





















factors are not easy to incorporate in the models such as the composition and pH of GI 
fluid, the gastric emptying, GI motility, mucus covering epithelium and blood and 
lymph flow.
15
 Therefore, in this section in vivo experiments in rats with Eudragit®FS 
30 D coated capsules filled with S2 solid (the two step system) to study biodistribution 
of the cargo (i.e. safranin O) were carried out. Moreover, in order to obtain a targeted 
system to the colon tissue, S2 were included in an enteric coated capsule with 
Eudragit®FS 30 D. Coating with Eudragit polymers is a well-established procedure in 
oral administration to target a drug to a particular intestinal segment based on the 
solubility of the polymer at the prevailing pH on the segment of interest, in this case the 
colon. With this purpose the nanoparticles were incorporated in an enteric coated form 
as the “first step” of the targeting strategy. Once in colon, it was expected the capped 
MSNs to accumulate into the tissue. Nanoparticles delivered their cargo inside de 
colonic cells after the exposition to the enzymatic stimuli (second step). An enhanced 
safranin O delivery in the colon was expected when using S2 when compared with the 
dye administered free as solution. In these studies, free and encapsulated dye within the 
nanoparticles S2 (1 mg/mL) were used at an equivalent concentration of safranin O. 
A comparison of safranin O distribution at 24 h in the colon, plasma and other organs 
(e.g. heart, pancreas, brain, kidney, spleen, liver and lung) in rats fed with a dye solution 
or with the S2-Eudragit®FS 30 D formulation is depicted in Figure 7. The results 
showed that when safranin O was administered free, it did not accumulate in the colon 
or in other organs, and was almost completely eliminated after 24 h. In contrast, a high 
dye content in colon tissue at 24 h was observed when safranin O was administered with 
the S2-Eudragit®FS 30 D formulation, whereas a very low content was found in blood 




Figure 7. Percentage of safranin O distributed in plasma and the tested tissues at 24 h 
after free (grey) or dye encapsulated in the S2 solid in rats (black).  
 
Safranin O distribution in the colon, plasma and other organs in rats fed with the S2-
Eudragit®FS 30 D formulation was studied at different times (e.g. 24 h, 48 h and 72 h) 
after administration (see Figure 8). In this case the results indicated that safranin O 
retention in colon tissue was much greater than in plasma and other organs at both 24 
and 48 h after administration. Moreover, the amount of safranin O in colon tissue 



















Figure 8. Percentage of safranin O in plasma and different tissues at 24 (black), 48 
(dark grey) and 72 h (light grey) after S2 administration. 
 
This enhanced distribution profile in the colon is highly desirable and beneficial for the 
administration of drugs that intend to exert effects on the colon, such as anti-
inflammatories, corticosteroids or immunosuppressant’s for inflammatory bowel 
diseases, or antitumor drugs for colon cancer. Moreover, the low levels of the model 
drug (safranin O) found in plasma and other tissues would imply significantly fewer 
undesirable systemic effects. 
 
4. CONCLUSIONS 
Local treatment of colon diseases, such as IBD or colorectal cancer, is preferable to 
systemic treatment to avoid systemic toxic effects, while preserving therapeutic efficacy 
by providing high concentrations of the drug in the target tissue. In this work, we tested 
three different gated MSNs loaded with safranin O and capped with molecules that 
contained a disulphide bond (S1), hydrolyzed starch (S2) and a lipid bilayer (S3). In the 
laboratory studies, the prepared MSNs showed near “zero delivery”, but were able to 
deliver cargo in the presence of the corresponding stimuli: (i) a reducing agent for S1, 
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toxicity in Caco-2 cells up to 72 h at the 1 mg/mL concentration. Moreover, the 
permeability of safranin O when encapsulated in S1, S2 and S3, compared to that of free 
dye, in Caco-2 monolayers (a standard model for drug transport across the intestinal 
mucosa) demonstrated that free safranin O rapidly diffused through the cell monolayer, 
whereas intracellular dye levels were significantly higher in the Caco-2 monolayer 
when using MSNs S1, S2 or S3. In cells, S1 opened and delivered cargo due to the high 
glutathione concentration inside cells; presence of amylase enzymes in lysosomes 
accounted for cargo delivery from S2, whereas in S3, delivery occurred when the 
capping lipid bilayer became fused with the cell membrane. Internalization in the Caco-
2 cells of S2 and S2b (fluorescein-labeled MSNs) was demonstrated by fluorescence 
microscopy studies. Internalization assays with several inhibitors indicated that the S2 
nanoparticles internalized via endocytosis, and suggested that several endocytosis 
mechanisms are active at the same time. Finally, in vivo experiments with S2 in rats to 
study cargo biodistribution (safranin O) were carried out. To obtain a targeted system to 
colon tissue, S2 were included in an enteric coated capsule with Eudragit®FS 30 D. The 
results showed that when safranin O was encapsulated in the S2-Eudragit®FS 30 D 
formulation, the dye content in colon tissue was significantly high, and a very low 
amount was found in blood and in other organs. This was a very appropriate 
biodistribution and suggested that this, or similar formulations, using gated MSNs could 
be suitable systems for the targeted controlled drug delivery in the colon with enhanced 
therapeutic effects and minimum undesirable effects. It could be potentially applied to a 
wide range of diseases, such as colorectal cancer and IBD. 
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